Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|30 CitationsImmunity & GutFemale-friendly

LL-37 Dosing Protocol: Antimicrobial Research Guide

Also known as: Cathelicidin Antimicrobial Peptide, hCAP18

Dose Range
250–500 mcgResearch range
0Typical research window: 250–500 mcg600 mcg

Studied in published research — not a medical recommendation. Primary protocol (Antimicrobial Study): Variable, N/A.

Protocol at a Glance
How Often
N/A

N/A

A Typical Run
N/A

Research-reported range; the linked study used a different dose or units.

How It's Taken
Vial

Topical/Inhalation

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 250 mcg10 units
High end: 500 mcg20 units

All U-100: 100 units = 1 mL. 20 doses in the vial at the low end (10 doses at the high end).

Track the doses you run

Save LL-37 (Cathelicidin) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 4 — Mechanistic / Early Preclinical
Pharmacological Class
Innate Host-Defense & Immunomodulatory Peptide
Administration Route
Under-the-skin injection (Topical/Inhalation)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 4 — Mechanistic / Early Preclinical: Receptor kinetics, cell culture, and early exploratory animal pharmacology
What is an Antimicrobial Peptide?

A naturally occurring peptide that your immune system uses to kill bacteria, viruses, and fungi. LL-37 (cathelicidin) is the most studied human antimicrobial peptide. These peptides punch holes in microbial cell membranes and also modulate immune responses.

Bottom Line Up Front

LL-37 is the only known human cathelicidin antimicrobial peptide. It has broad-spectrum antimicrobial activity and immune-modulating properties. Part of the innate immune system.

Best evidence for

Antimicrobial activity, immune modulation

Weakest evidence for

Systemic infection treatment in humans

Pharma equivalent

None

Studies on file

30 (27 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. LL-37 (Cathelicidin) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

LL-37 is the only known human cathelicidin antimicrobial peptide. It plays a crucial role in innate immunity and has been studied for its antimicrobial, immunomodulatory, and wound healing properties.

Mechanisms of Action

  • Direct antimicrobial activity against bacteria, viruses, fungi
  • Modulates immune cell chemotaxis
  • Promotes wound healing
  • Regulates inflammatory responses
  • Influences angiogenesis

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Antimicrobial Study
in vitro
VariableN/AN/ATopical/Inhalationin vitro
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (LL-37 (Cathelicidin))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

27 Human1 Animal2 In Vitro

Mechanistically, LL-37-induced CXCL10 production relied on the Jak1/signal transducer and activator of transcription 1 signaling pathway. In summary, our findings provide a crucial link to keratinocyte-T-cell crosstalk, and blockade of the CXCL10:CXCR3 axis or Jak1/signal transducer and activator of transcription 1 pathways can be an effective anti-inflammatory strategy to reduce rosacea inflammation by restricting pathogenic T-cell infiltration.

Limitations: No placebo control reported.

2026|The Journal of investigative dermatology
PubMed

These immunomodulatory actions occurring at concentrations lower than those microbicidal uncover a new guise for cathelicidin modulating the epithelial barrier against A/E pathogens. Recognizing native cathelicidin's functions in a specified disease setting (e.g., colitis) will help establish it as an anti-infectious immunomodulator.

Limitations: No placebo control reported.

2025|Biochimica et biophysica acta. Biomembranes
PubMed

Finally, the LL-37-induced EndMT was inhibited by Akt and nuclear factor-kappa B (NF-&#x3ba;B) inhibitors, suggesting that LL-37 induces EndMT by activating Akt and NF-&#x3ba;B. These observations speculate a role of LL-37 in the pathogenesis of atherosclerosis as an EndMT inducer.

Limitations: No placebo control reported.

2025|Bioscience, biotechnology, and biochemistry
PubMed

LL-37 was expressed in macrophages and myofibroblasts of capsular tissue in 10 (34%) and nine (31%) of the specimens, respectively. In eight cases (27.5%), it was expressed by both macrophages and myofibroblasts of the same specimen.

Limitations: No placebo control reported.

2024|Plastic and reconstructive surgery
PubMed

The effect of LL-37 is time-dependent. As a result, LL-37 may provide rapid and affordable therapies for RVFV infection in Egypt, both during outbreaks and as a preventive strategy.

Limitations: No placebo control reported.

2024|Cellular and molecular biology (Noisy-le-Grand, France)
PubMed

Interestingly, synthetic LL-37, at this concentration, reduces viability of human osteoblast-like MG63&#xa0;cells, whereas the THP-1&#xa0;cells are less sensitive as demonstrated by the MTT assay. In summary, we show that vitamin D enhances hCAP18/LL-37 production, and that this effect can be of physiological/pathophysiological relevance for LL-37-induced human osteoblast toxicity.

Limitations: No placebo control reported.

2024|Biochemical and biophysical research communications
PubMed

This review provides a comprehensive discussion of research highlighting the beneficial health effects of LL-37/nucleic acid complexes, as well as discussing observed detrimental effects. We will emphasize why it is important to investigate and elucidate structural characteristics, such as condensation patterns of nucleic acids within complexation, and their mechanisms of action, to shed light on the intricate physiological effects of LL-37 and the seemingly contradictory role of LL-37/nucleic acid complexes in the innate immune response.

Limitations: No placebo control reported. Review article — no new primary data.

2024|Biophysical journal
PubMed

Oral LL-37 expression is an important factor in oral homeostasis that maintains the physiological microbiota but is also involved in the development of oral dysbiosis, infectious diseases (including viral, bacterial, and fungal infections), autoimmune diseases, and oral carcinomas. This peptide has also been proposed as a marker of inflammation severity and treatment outcome.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2024|Biomedicines
PubMed

In addition, cathelicidin LL-37 inhibited the cell cycle and accumulated cells in the S phase. Therefore, these results specify the potential of cathelicidin LL-37 for developing a new and effective anti-Candida agent.

Limitations: In-vitro study — may not reflect in-vivo effects.

2024|Journal of fungi (Basel, Switzerland)
PubMed

Interestingly, the LL-37&#x2012;induced distribution of tight junction proteins and improvement in the tight junction barrier were inhibited in autophagy-deficient keratinocytes and keratinocytes and skin models treated with autophagy inhibitors, indicating that the LL-37&#x2012;mediated tight junction barrier is associated with autophagy activation. Collectively, these findings suggest that LL-37 is a potential therapeutic target for skin diseases characterized by dysfunctional autophagy and skin barriers.

Limitations: No placebo control reported.

2023|The Journal of investigative dermatology
PubMed

coli load in the liver and spleen (P&#xa0;<&#xa0;0.01) and restored the structure of the liver and kidney. Taken together, LL-37 conferred protection in a EHEC O157:H7-induced mouse model by reducing intestinal inflammation, enhancing intestinal barrier function, and restoring the balance of the intestinal microbiota, which indicates the therapeutic potential of LL-37 against pathogen infection.

Limitations: No placebo control reported.

2023|Peptides
PubMed

In terms of its efficacy and safety in vivo, there are still many questions to be answered. Undoubtedly, LL-37 can open up new windows of opportunity to prevent and treat obstinate biofilm-mediated infections.

Limitations: No placebo control reported. Review article — no new primary data.

2023|World journal of microbiology &amp; biotechnology
PubMed

Taken together, these observations suggest that LL-37 induces autophagy in endothelial cells but enhances cell death in autophagy-dysfunctional conditions, in which the intracellular degradation of LL-37 is disturbed. Thus, LL-37 may exert an adverse action on autophagy-dysfunctional endothelial cells to induce cell death in the pathogenesis of atherosclerosis.

Limitations: No placebo control reported.

2022|Journal of immunology (Baltimore, Md. : 1950)
PubMed

In addition, it has been postulated that LL-37 can directly bind the S1 domain of SARS-CoV-2, mask angiotensin converting enzyme 2 (ACE2) receptors, and limit SARS-CoV-2 infection. Purposeful upregulation of LL-37 could also serve as a preventative and therapeutic strategy for SARS-CoV-2 infections.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Frontiers in immunology
PubMed

Altogether, our results suggest a "carpet" membrane dissolution followed by a detergent-like membrane disruption mechanism upon LL-37 activity. This research gives a novel insight into the understanding of LL-37 influence on multicomponent model membranes and a promising contribution to the development of LL-37-derived therapeutic agents against drug-resistant bacteria.

Limitations: No placebo control reported.

2021|Bioelectrochemistry (Amsterdam, Netherlands)
PubMed

Pretreatment with the FPRL1 antagonist inhibited LL-37-induced phosphorylation of ERK and Akt proteins and attenuated LL-37-induced HDLEC migration and tube-like formation. These data indicated that LL-37 induces lymphangiogenesis in lymphatic endothelial cells via FPRL1, and the activation of the ERK and Akt-dependent signaling pathways.

Limitations: No placebo control reported.

2021|Molecular biology reports
PubMed

Diseased sites had significantly (P <0.05) higher levels of LL-37 and lower levels of HNP 1-3 than healthy sites in both smokers and non-smokers. Diseased sites of smokers presented significantly lower levels of LL-37 and HNP 1-3 when compared with diseased sites of non-smokers.

Limitations: No placebo control reported.

2021|Journal of periodontology
PubMed

Between others, they demonstrate high clinical potential as antimicrobial, anti-cancer, immunomodulatory and regenerative agents. Due to continuous research, knowledge on pleiotropic character of natural antibacterial peptides and their mimics is growing, and it is justifying to stay that the therapeutic potential of nanosystems containing membrane active compounds has not been exhausted yet.

Limitations: No placebo control reported. Review article — no new primary data.

2020|Journal of nanobiotechnology
PubMed

LL-37 treatment dramatically increased IFN&#x3b2;1 expression in treated cells in a time-dependent manner. Our results establish LL-37 as a relevant and novel potential therapeutic strategy for the treatment of VEEV infections.

Limitations: No placebo control reported.

2020|Antiviral research
PubMed

Also discussed are other application strategies, including peptide formulation, antimicrobial implants, and peptide-inducing factors such as vitamin D and sunlight. Finally, we summarize what we learned from peptide design based on human LL-37.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Advances in experimental medicine and biology
PubMed

Given that the phenotypic and functional properties of immune compartments are different and significantly impacted by the anatomical sites, tissue-specific factors of host origin and microbial communities play important roles in the regulation of LL-37. This review summarizes the expression and biological functions of LL-37 and discusses its significant roles in the innate immune system based on its anatomical distribution.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Current pharmaceutical design
PubMed

Meanwhile, the findings that vitamin D-dependent induction of cathelicidin in human macrophages activates the anti-cancer activity of tumor-associated macrophages (TAMs) and enhances antibody-dependent cellular cytotoxicity (ADCC) support critical roles of vitamin D-dependent induction of cathelicidin in cancer progression. This review describes novel advances involving the roles and mechanisms of human cathelicidin LL-37 in cancer.

Limitations: No placebo control reported. Review article — no new primary data.

2018|Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
PubMed

EGCG killed 100&#xa0;% of planktonic S. mutans within 5&#xa0;h, inhibited biofilm formation within 24&#xa0;h, and reduced bacteria cells in preformed biofilms within 3&#xa0;h at a concentration of 0.2&#xa0;mg/mL.

Limitations: No placebo control reported.

2018|BMC oral health
PubMed

Sixty-three post-infectious BO patients and 65 healthy children (median age 73&#x2009;&#xb1;&#x2009;55 and 78.74&#x2009;&#xb1;&#x2009;36.32 months, respectively) were enrolled in the study. The mean of hBD2 levels in patients and the control group were 1.06&#x2009;&#xb1;&#x2009;0.24 and 0.67&#x2009;&#xb1;&#x2009;0.72 ng/mL, respectively (P&#x2009;<&#x2009;0.001).

Limitations: Standard limitations apply. Check original paper for full discussion.

2017|The clinical respiratory journal
PubMed

We analyzed the main molecular pathways dependent on human cathelicidin and related them to specific diseases. We conclude that LL-37 shows a great potential to be further investigated and developed as a drug with clinical use.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Pharmacological reports : PR
PubMed

Cathelicidin peptides could serve as a template for the development of modern anti-microbial and anti-viral drugs. LL-37 is an excellent candidate to develop into therapeutics for infected wounds.

Limitations: No placebo control reported. Review article — no new primary data.

2016|BioFactors (Oxford, England)
PubMed

We also consider its different membrane-dependent effects on our own cells, which underlie many of its other activities in host defence. This article is part of a Special Issue entitled: Pore-Forming Toxins edited by Mauro Dalla Serra and Franco Gambale.

Limitations: No placebo control reported. Review article — no new primary data.

2016|Biochimica et biophysica acta
PubMed

Furthermore, LL-37 reduced phosphorylation of Src kinase and Akt(Ser473), decreased platelet spreading on immobilized fibrinogen and inhibited P-selectin expression on platelets. These results demonstrate that LL-37 has antiplatelet and antithrombotic actions.

Limitations: No placebo control reported.

2016|Biochemical and biophysical research communications
PubMed

This discrepancy can be attributed to peptide-based factors, host membrane-based factors, and signal regulation. Here, we describe the association between AMPs and cancer with a focus on anticancer peptide functions and selectivity in an effort to understand potential therapeutic implications.

Limitations: In-vitro study — may not reflect in-vivo effects. Review article — no new primary data.

2015|Frontiers in oncology
PubMed

The mechanistic results from this study suggest that regulation of immune-mediated inflammation by these peptides may be controlled by the dual phosphatase MKP-1. We speculate that LL-37 and its derivatives may contribute to the control of immune-mediated inflammatory diseases.

Limitations: No placebo control reported.

2014|Immunology
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Limited human clinical data
  • •May trigger inflammatory responses in some contexts
  • •Research primarily in vitro and animal models
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get LL-37 (Cathelicidin), baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Trusted Voices

X/Twitter accounts discussing this peptide

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.